Efficacy and Safety of Single-Agent Zandelisib Administered By Intermittent Dosing in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Final Results of the Tidal Phase 2 Study

被引：4
|
作者：
Zelenetz, Andrew D. [1 ]
Jurczak, Wojciech [2 ]
Ribrag, Vincent [3 ]
Linton, Kim M. [4 ,5 ]
Collins, Graham P. [6 ]
Bishton, Mark [7 ]
Lopez Jimenez, Javier [8 ]
Dholaria, Bhagirathbhai [9 ]
Mengarelli, Andrea [10 ]
Phillips, Tycel J. [11 ]
Sungala, Nagendra Prasad [12 ]
Chan, Henry [13 ]
Musuraca, Gerardo [14 ]
Sheehy, Oonagh [15 ]
Yan, Junyi [16 ]
Xu, Weiming [16 ]
Azoulay, Michel [17 ]
Zinzani, Pier Luigi [18 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland
[3] Gustave Roussy Canc Campus, Villejuif, France
[4] Christie NHS Fdn Trust, Manchester, Lancs, England
[5] Manchester Canc Res Ctr, Manchester, Lancs, England
[6] Oxford Univ Hosp NHS Fdn Trust, Churchill Hosp, Oxford, England
[7] Nottingham Univ Hosp, Nottingham, England
[8] Hosp Univ Ramon y Cajal, Hematol Serv, Madrid, Spain
[9] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol & Oncol, Nashville, TN USA
[10] Regina Elena Inst Canc Res, Rome, Italy
[11] Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI 48109 USA
[12] Liverpool Hosp, Dept Haematol, Sydney, NSW, Australia
[13] North Shore Hosp, Auckland, New Zealand
[14] Ist Sci Romagnolo Studio & Cura Tumori, Meldola, Italy
[15] Belfast HSC Trust, Belfast, Antrim, North Ireland
[16] MEI Pharma Inc, San Diego, CA USA
[17] Kyowa Kirin Co, Princeton, NJ USA
[18] Univ Bologna, Inst Hematol Seregnoli, Bologna, Italy
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-165409
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3595 / 3597
页数：3
相关论文
共 50 条
  • [21] Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1-3a: Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
    Kim, Tae Min
    Taszner, Michal
    Cho, Seok-Goo
    Novelli, Silvana
    Le Gouill, Steven
    Poon, Michelle Limei
    Villasboas, Jose C.
    Champion, Rebecca
    Bachy, Emmanuel
    Guidez, Stephanie
    Alonso, Aranzazu Alonso
    Jagadeesh, Deepa
    Merli, Michele
    Tucker, David
    Cai, Jingxian
    De Oliveira, Carolina Leite
    Zhu, Min
    Chaudhry, Aafia
    Mohamed, Hesham
    Ambati, Srikanth R.
    Luminari, Stefano
    BLOOD, 2022, 140 : 2280 - 2282
  • [22] Subcutaneous Epcoritamab With Rituximab plus Lenalidomide (R2) in Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Update from Phase 1/2 Trial
    Falchi, Lorenzo
    Leppa, Sirpa
    Wahlin, Bjorn E.
    Nijland, Marcel
    Christensen, Jacob Haaber
    De Vos, Sven
    Holte, Harald
    Linton, Kim M.
    Abbas, Aqeel
    Wang, Liwei
    Dinh, Minh
    Elliott, Brian
    Belada, David
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S392 - S392
  • [23] Schedule of bortezomib administration may be an important determinant of single-agent activity in patients with relapsed or refractory follicular (FL) lymphoma and mantle cell lymphoma (MCL)
    O'Connor, O.
    Hamlin, P.
    Moskowitz, C.
    Straus, D.
    Noy, A.
    Wright, J.
    Neylon, E.
    MacGregor-Cortelli, B.
    Portlock, C.
    Zelenetz, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [24] Single-agent everolimus (RAD001) in patients with relapsed or refractory multiple myeloma: Final results of a phase I study
    Guenther, A.
    Baumann, P.
    Burger, R.
    Klapper, W.
    Schmidmaier, R.
    Gramatzki, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [25] TRANSCEND FL: Phase II Study Results of Lisocabtagene Maraleucel (Liso-Cel) in Patients With R/R Follicular Lymphoma (FL)
    Nastoupil, Loretta J.
    Dahiya, Saurabh
    Palomba, M. Lia
    Martin Garcia-Sancho, Alejandro
    Reguera Ortega, Juan Luis
    Kuruvilla, John
    Jager, Ulrich
    Cartron, Guillaume
    Izutsu, Koji Izutsu
    Dreyling, Martin
    Kahl, Brad
    Ghesquieres, Herve
    Ardeshna, Kirit
    Goto, Hideki
    Barbui, Anna Maria
    Abramson, Jeremy S.
    Borchmann, Peter
    Fleury, Isabelle
    Mielke, Stephan
    Farazi, Thalia
    Fasan, Omotayo
    Lymp, James
    Vedal, Min
    Nishii, Rina
    Avilion, Ariel
    Papuga, Jessica
    Morschhauser, Frank
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S447 - S448
  • [26] Analyzing Efficacy Outcomes from the Phase 2 Study of Single-Agent Tazemetostat As Third-Line Therapy in Patients with Relapsed or Refractory Follicular Lymphoma to Identify Predictors of Response
    Salles, Gilles
    Tilly, Herve
    Chaidos, Aristeidis
    Mckay, Pam
    Phillips, Tycel J.
    Assouline, Sarit E.
    Batlevi, Connie Lee
    Campbell, Philip
    Ribrag, Vincent
    Damaj, Gandhi Laurent
    Dickinson, Michael
    Jurczak, Wojciech
    Kazmierczak, Maciej
    Opat, Stephen
    Radford, John A.
    Schmitt, Anna
    Whalen, Jennifer
    Hamlett, Anthony
    Kamp, Beth
    Adib, Deyaa
    Morschhauser, Franck
    BLOOD, 2020, 136
  • [27] Analyzing Efficacy Outcomes From the Phase 2 Study of Single-Agent Tazemetostat as Third-Line Therapy in Patients With Relapsed or Refractory Follicular Lymphoma to Identify Predictors of Response
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 2 - 3
  • [28] Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
    Budde, Lihua E.
    Sehn, Laurie H.
    Matasar, Matthew
    Schuster, Stephen J.
    Assouline, Sarit
    Giri, Pratyush
    Kuruvilla, John
    Canales, Miguel
    Dietrich, Sascha
    Fay, Keith
    Ku, Matthew
    Nastoupil, Loretta
    Cheah, Chan Yoon
    Wei, Michael C.
    Yin, Shen
    Li, Chi-Chung
    Huang, Huang
    Kwan, Antonia
    Penuel, Elicia
    Bartlett, Nancy L.
    LANCET ONCOLOGY, 2022, 23 (08): : 1055 - 1065
  • [29] Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study
    Salles, Gilles
    Schuster, Stephen J.
    de Vos, Sven
    Wagner-Johnston, Nina D.
    Viardot, Andreas
    Blum, Kristie A.
    Flowers, Christopher R.
    Jurczak, Wojciech J.
    Flinn, Ian W.
    Kahl, Brad S.
    Martin, Peter
    Kim, Yeonhee
    Shreay, Sanatan
    Will, Matthias
    Sorensen, Bess
    Breuleux, Madlaina
    Zinzani, Pier Luigi
    Gopal, Ajay K.
    HAEMATOLOGICA, 2017, 102 (04) : E156 - E159
  • [30] Long-term safety and efficacy of single-agent lbrutinib in patients with relapsed or refractory mantle cell lymphoma: Updated results of an international, multicenter, open-label phase 2 study
    Dreyling, M.
    Wang, M. L.
    Rule, S.
    Martin, P.
    Goy, A.
    Auer, R.
    Kahl, B. S.
    Jurczak, W.
    Advani, R. H.
    Romaguera, J. E.
    Williams, M. E.
    Barrientos, J. C.
    Chmielowska, E.
    Radford, J.
    Stilgenbauer, S.
    Jedrzejczak, W. W.
    Johnson, P.
    Spurgeon, S. E.
    Zhang, L.
    Baher, L.
    Cheng, M.
    Beaupre, D. M.
    Blum, K. A.
    Oncology Research and Treatment, 2015, 38 : 18 - 19
12345